characterized by fluctuating airways obstruction, with diurnal variation and nocturnal
exacerbations. SS: the triad of wheeze, cough and breathlessness. due to a combination of constriction of bronchial smooth muscle, edema of the mucosa lining the small bronchi, and plugging of the bronchial lumen with viscous mucus and inflammatory cells categorized into non-allergic and allergic, but there is considerable overlap. In allergic asthma, which is usually of early onset, extrinsic allergens produce a type I allergic reaction in atopic subjects. Type I reactions are triggered via reaginic antibodies (IgE) , eosinophils. Patients with non-allergic (late-onset) asthma do not appear to be sensitive to any single well- defined antigen, although infection (usually viral) often precipitates an attack. Inflammatory mediators implicated in asthma include histamine, several leukotrienes (LTC4/D4 and E4) 5-hydroxytrypta- mine (serotonin), prostaglandin D2, platelet-activating factor (PAF), neuropeptides and tachykinins. Adrenaline:anticholinergic:muscarinic: bronchoconstriction. Ach:B receptors:bronchodilation
COPD Acute exacerbation Controlled oxygen therapy (e.g. FiO2 2428%); Nebulized 2-agonists (salbutamol every 24 hours, if needed) or intravenously if refractory; Nebulized anticholinergics, such as ipratropium bromide; Antibiotics (e.g. clarithromycin, co-amoxiclav, levofloxacin). Short-term oral prednisolone.
Chronic disease Stop smoking cigarettes. Optimize inhaled bronchodilators (salbutamol/ipratropium bromide) and their administration. Consider oral theophylline and/or inhaled glucocorticosteroids. Treat infection early and aggressively with antibiotics. Offer long-term oxygen therapy (LTOT) for at least 15 hours per day for cor pulmonale. Diuretics should be used for peripheral oedema. Consider venesection for severe secondary polycythaemia. Exercise, within limits of tolerance.
Terbutaline similar to salbutamol Salmeterol: prophylaxis to exercised induced asthma
Bronchodilator agents 2-Agonists. Bronchodilate by increasing intracellular cAMP. Short-acting, rapid-onset agents (e.g. salbutamol) are used as needed to relieve bronchospasm in asthma. Long-acting, slower-onset agents (e.g. salmeterol) are used regularly twice daily. Common side effects include tremor, tachycardias, vasodilatation, hypokalaemia and hyperglycaemia.
Anticholinergics Antagonist at M2 and M3 muscarinic receptors in the bronchi, causing bronchodilatation. Slow onset of long-lasting bronchodilatation (given six- to eight-hourly), especially in older patients. Bitter taste.
Anti-inflammatory agents cromoglicate and glucocorticosteroids Sodium cromoglicate Its mechanism of action is unclear. It has an anti- inflammatory effect. Largely superseded in chronic prophylactic therapy of allergic asthma by glucocorticosteroids. Prevents exercise-induced asthma. Inhaled therapy is administered via metered-dose inhaler or dry powder. Side-effects are minimal (headache, cough). Its use is very safe in children.
Glucocorticosteroids Mechanism is anti-inflammatory. They are administered systemically (i.v./p.o.) in severe acute and chronic asthma. They are inhaled topically or nebulized in chronic asthma. Glucocorticosteroids are well absorbed from the gastro- intestinal tracthepatic (CYP3A) metabolism. Dosing is once daily for oral glucocorticosteroids and twice daily for inhaled agents. Side effects are minimal with topical therapy (oral thrush, hoarse voice, HPA suppression only at high dose). Side effects with systemic therapy are the features of Cushings syndrome.
Leukotriene modulation in asthma Leukotriene B4 is a powerful chemo-attractant (eosinophils and neutrophils) and increases vascular permeability producing mucosal oedema. Leukotrienes C4, D4 and E4 (cysteinyl leukotrienes) are potent spasmogens and pro-inflammatory substances (SRS-A). Clinically used agents that modulate leukotrienes are leukotriene antagonists (which antagonize cysteinyl leukotrienes LTD4, LTC4 at the Cys-LT1 receptor) Leukotriene antagonists (e.g. montelukast) are effective as oral maintenance therapy in chronic persistent asthma. Montelukast has antiinflammatory properties and is a mild, slow-onset bronchodilator. Accolate (zafirlukast) is a leukotriene modifier and is used for the prophylaxis and chronic treatment of asthma
Adverse Effects of Theophylline: - Dose related acute toxicities include: tachycardia, nausea and vomiting, tachyarrhythmias (SVT), central nervous system stimulation, headache, seizures, hematemesis, hyperglycemia, and hypokalemia. - Adverse effects at usual therapeutic doses: insomnia, gastric upset, aggravation of ulcer or reflux, increase in hyperactivity in some children, and difficulty in urination in elderly males with prostatism.
Respiratory failure Type I (hypocapnic hypoxaemia) and type II (hypercapnic hypoxaemia). Therapy for type I is supportive with high-percentage oxygen (FiO2 4060%). Therapy for type II is low-percentage oxygen (FiO2 2428%) and treatment of reversible factors infection and bronchospasm (with antibiotics, bronchodilators and glucocorticosteroids). Type I or type II respiratory failure may necessitate mechanical ventilation. Central nervous system (CNS)-depressant drugs (e.g. opiates, benzodiazepines) may exacerbate or precipitate respiratory failure, usually type II. Sedatives are absolutely contraindicated (unless the patient is already undergoing mechanical ventilation).
FVC: Forced Vital Capacity - This is the total amount of air that you can forcibly blow out after full inspiration, measured in liters. FEV 1 : Forced Expiratory Volume in 1 Second - This is the amount of air that you can forcibly blow out in one second, measured in liters. Along with FVC it is considered one of the primary indicators of lung function. FEV 1 / FVC - This is the ratio of FEV 1 and FVC, which showing the amount of the FVC that can be expelled in one second. In healthy adults this should be approximately 80%. PEF: Peak Expiratory Flow - This is the speed of the air moving out of your lungs at the beginning of the expiration, measured in liters per second.